Tepotinib
Sign in to save this workspacePrimary targets: C_MET · FDA status: FDA Approved
Selectivity scorecard
KISS
99.75
Gini
0.727
CATDS
0.042
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Tepotinib. Strongest target: C_MET at 95.2% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | C_MET | 95.2% | 4.8% |
| 2 | TRKC | 86.2% | 13.8% |
| 3 | IRAK4 | 72.7% | 27.3% |
| 4 | IRAK1 | 72.6% | 27.4% |
| 5 | FGFR2 | 72.6% | 27.4% |
| 6 | AXL | 69.6% | 30.4% |
| 7 | FGFR1 | 62.3% | 37.7% |
| 8 | MELK | 50.4% | 49.6% |
| 9 | FGFR3 | 49.8% | 50.2% |
| 10 | FGFR4 | 49.2% | 50.8% |
| 11 | TRKB | 33.1% | 66.9% |
| 12 | STK39_STLK3 | 30.5% | 69.5% |
| 13 | FLT4_VEGFR3 | 28.5% | 71.5% |
| 14 | FLT1_VEGFR1 | 28.2% | 71.8% |
| 15 | BMPR2 | 25.1% | 74.9% |
| 16 | ALK | 24.9% | 75.1% |
| 17 | LYN | 24.9% | 75.1% |
| 18 | CAMK1G | 23.4% | 76.6% |
| 19 | LCK | 19.9% | 80.1% |
| 20 | GSK3B | 18.7% | 81.3% |
Selectivity landscape
Where Tepotinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Tepotinib.
Annotations
Sign in to read and post annotations.
Loading…